Express News | Windward Bio: Orbimed, Novo Holdings, and Blue Owl Healthcare Opportunities Lead Series a Financing of $200M

Reuters39minutes ago

Express News | Windward Bio Launches With $200 Million Series a Financing to Develop Phase 2-Ready, Long-Acting Anti-Tslp Antibody With Best-in-Class Potential in Asthma and Copd

Reuters43minutes ago

SKB BIO-B (06990.HK) has entered into an exclusive licensing agreement with Windward Bio AG regarding SKB378/HBM9378.

Gelonghui, January 10th | SKB BIO-B (06990.HK) announced that the company and Huanbo Pharmaceutical Holdings Limited (collectively referred to as "the Licensors") have signed an exclusive license agreement with Windward Bio AG for the jointly developed monoclonal antibody (mAb) SKB378/HBM9378 targeting thymic stromal lymphopoietin (TSLP). According to the terms and conditions of the license agreement, Windward Bio is granted SKB378/HBM9378 globally (excluding Greater China and parts of Southeast Asia and Western Asia).

Gelonghui Finance08:12 ET

Express News | Hbm Holdings - License Agreement Excludes Greater China and Several Southeast and West Asian Countries

Reuters08:02 ET

Express News | Hbm Holdings - License Agreement to Grant Windward Bio an Exclusive Worldwide License to Manufacture, Among Others, Hbm9378/Skb378

Reuters08:02 ET

CMB International: With continued policy efforts, Bullish on the rebound of China Meheco Group's valuation.

Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a high-elasticity Industry, is expected to outperform the market in 2025.

Zhitong FinanceJan 8 03:34 ET